2DR Stock Chart & Stats
€47.60
€6.05(3.07%)
At close: 4:00 PM EST
€47.60
€6.05(3.07%)
Day’s Range― - ―
52-Week Range€33.60 - €121.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.25B
Enterprise Value€1.23K
Total Cash (Recent Filing)€283.83M
Total Debt (Recent Filing)€29.55M
Price to Earnings (P/E)10.9
Beta0.42
Next Earnings
Aug 03, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.53
Shares Outstanding28,813,152
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.91Price Target Upside-3.55% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)0.79
Revenue Forecast (FY)€737.14M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained ~85%+ gross margins indicate a differentiated product cost structure and pricing power in the OSA implant market. High gross margins provide durable earnings leverage as procedures scale, supporting profitability resilience even if volumes dip during reimbursement disruptions.
Strong Operating Cash GenerationConsistent positive operating cash flow and meaningful FCF create financial flexibility to fund commercialization, clinical trials, and working-capital needs without issuing debt. This cash generation buffers near-term revenue cyclicality and underpins strategic investments through reimbursement disruption periods.
Conservative Balance Sheet, Low LeverageVery low leverage and a sizable cash position reduce refinancing and liquidity risk, enabling the company to sustain operations, invest in reimbursement/education efforts, and support clinical programs while revenue recovers, a long-term advantage in a regulatory-sensitive medical device market.
Bears Say
Coding And Reimbursement UncertaintyOngoing code ambiguity and phased-out CPT create a multi-year headwind to case submissions and payer approvals. Until a standard CPT is adopted (expected 2028), manual reviews and inconsistent payer coding will structurally slow procedure volume, complicate planning and constrain durable revenue growth.
WISER Prior-authorization Pilot ImpactThe AI-reviewed WISER prior-authorization pilot has materially delayed Medicare approvals and reduced procedures. As the pilot expands or persists, it can create sustained regional variability in access and revenue, forcing longer-term operational changes and increased reimbursement staffing costs.
Profitability And Cash-flow Variability; Tax VolatilityWhile cash flow is positive overall, FCF and margins have shown variability and episodic tax volatility from equity comp can swing GAAP results. Such inconsistency complicates forward earnings visibility and capital allocation decisions, reducing predictability for the next several quarters.
Inspire Medical Systems News
2DR FAQ
What was Inspire Medical’s price range in the past 12 months?
Inspire Medical lowest stock price was €33.60 and its highest was €121.90 in the past 12 months.
What is Inspire Medical’s market cap?
Inspire Medical’s market cap is €1.25B.
When is Inspire Medical’s upcoming earnings report date?
Inspire Medical’s upcoming earnings report date is Aug 03, 2026 which is in 8 days.
How were Inspire Medical’s earnings last quarter?
Inspire Medical released its earnings results on May 04, 2026. The company reported €0.088 earnings per share for the quarter, beating the consensus estimate of -€0.242 by €0.329.
Is Inspire Medical overvalued?
According to Wall Street analysts Inspire Medical’s price is currently Overvalued.
Does Inspire Medical pay dividends?
Inspire Medical does not currently pay dividends.
What is Inspire Medical’s EPS estimate?
Inspire Medical’s EPS estimate is -0.21.
How many shares outstanding does Inspire Medical have?
Inspire Medical has 28,813,152 shares outstanding.
What happened to Inspire Medical’s price movement after its last earnings report?
Inspire Medical reported an EPS of €0.088 in its last earnings report, beating expectations of -€0.242. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Inspire Medical?
Currently, no hedge funds are holding shares in DE:2DR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€45.91 (-3.55% Downside)
€45.91 (-3.55% Downside)
Blogger Sentiment
Bullish
DE:2DR Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €126.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.71%
Trailing 12-Months
Company Description
Inspire Medical
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
2DR Revenue Breakdown
97.02% U.S.
2.98% Other
2DR Stock 12 Month Forecast
Average Price Target
€45.91
▼(-3.55% Downside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
TransMedics Group
―
PROCEPT BioRobotics
―